Nonproliferative Diabetic Retinopathy

ROME — One-year results of the phase 2 ALTITUDE trial showed efficacy and safety of a one-time in-office injection of ABBV-RGX-314 for the treatment of diabetic retinopathy.

EyePoint Pharmaceuticals has announced positive interim masked safety data for its investigational EYP-1901 for treatment of moderate to severe nonproliferative diabetic retinopathy and wet age-related macular degeneration.

EyePoint Pharmaceuticals completed enrollment in the phase 2 PAVIA clinical trial to assess EYP-1901 for the treatment of moderate to severe nonproliferative diabetic retinopathy, according to a press release.

Should patients with nonproliferative diabetic retinopathy be treated early with prophylactic anti-VEGF therapy?

New results suggest that proactive treatment of severe nonproliferative diabetic retinopathy with aflibercept injections may lead to improvement of disease severity.

Patients with diabetic macular edema who had their treatment delayed during the first months of the COVID-19 pandemic experienced worsening of DME and retinopathy with consequent vision loss, according to a study carried out in the U.K.

WAILEA, Hawaii — In this video from Retina 2021, Christina Y. Weng, MD, MBA, discusses the impact of the recent DRCR Retina Network Protocol W, looking at the treatment of moderate to severe nonproliferative diabetic retinopathy with aflibercept.

In this video from the virtual American Society of Retina Specialists meeting, Geeta Lalwani, MD, discusses a large study looking at groups of diabetic patients at risk for progression to sight-threatening diabetic retinopathy.

Presentations from the virtual Association for Research in Vision and Ophthalmology meeting were released in May and June.